An image from Graphite Bio's new corporate campaign illustrates its Cure ambitions

Graphite Bio de­buts cor­po­rate brand cam­paign with ‘Cure’ as­pi­ra­tions, even years ahead of drug ap­proval

It’s tough to stand out in the gene edit­ing field, so Graphite Bio adopt­ed an un­com­mon biotech tac­tic — mar­ket­ing.

The clin­i­cal-stage biotech — found­ed dur­ing the ear­ly days of the pan­dem­ic and go­ing pub­lic just over a year ago — is still like­ly many years away from an ap­proved drug. Its first, a sick­le cell dis­ease “gene cor­rec­tion” can­di­date, is cur­rent­ly in a Phase I/II study. Yet the biotech’s first cor­po­rate cam­paign rolled out this month con­fi­dent­ly pro­motes its am­bi­tions for a cure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.